SE9002671L - Nya peptider, diagnostiska antigener, anvaendning daerav och vacciner - Google Patents

Nya peptider, diagnostiska antigener, anvaendning daerav och vacciner

Info

Publication number
SE9002671L
SE9002671L SE9002671A SE9002671A SE9002671L SE 9002671 L SE9002671 L SE 9002671L SE 9002671 A SE9002671 A SE 9002671A SE 9002671 A SE9002671 A SE 9002671A SE 9002671 L SE9002671 L SE 9002671L
Authority
SE
Sweden
Prior art keywords
diagnostic
vaccines
antigenes
peptides
new peptides
Prior art date
Application number
SE9002671A
Other languages
English (en)
Other versions
SE9002671D0 (sv
SE470074B (sv
Inventor
J Blomberg
Original Assignee
Replico Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replico Medical Ab filed Critical Replico Medical Ab
Priority to SE9002671A priority Critical patent/SE470074B/sv
Publication of SE9002671D0 publication Critical patent/SE9002671D0/sv
Priority to EP91915656A priority patent/EP0546031A1/en
Priority to PCT/SE1991/000542 priority patent/WO1992003475A1/en
Priority to AU84002/91A priority patent/AU649473B2/en
Publication of SE9002671L publication Critical patent/SE9002671L/sv
Publication of SE470074B publication Critical patent/SE470074B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
SE9002671A 1990-08-16 1990-08-16 Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider SE470074B (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9002671A SE470074B (sv) 1990-08-16 1990-08-16 Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider
EP91915656A EP0546031A1 (en) 1990-08-16 1991-08-16 Enterovirus peptides
PCT/SE1991/000542 WO1992003475A1 (en) 1990-08-16 1991-08-16 Enterovirus peptides
AU84002/91A AU649473B2 (en) 1990-08-16 1991-08-16 Enterovirus peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002671A SE470074B (sv) 1990-08-16 1990-08-16 Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider

Publications (3)

Publication Number Publication Date
SE9002671D0 SE9002671D0 (sv) 1990-08-16
SE9002671L true SE9002671L (sv) 1992-02-17
SE470074B SE470074B (sv) 1993-11-01

Family

ID=20380170

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9002671A SE470074B (sv) 1990-08-16 1990-08-16 Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider

Country Status (4)

Country Link
EP (1) EP0546031A1 (sv)
AU (1) AU649473B2 (sv)
SE (1) SE470074B (sv)
WO (1) WO1992003475A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
BE1022174B1 (fr) * 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT384363B (de) * 1982-10-05 1987-11-10 Immuno Ag Verfahren zur verwendung von antigenreaktiven peptiden zur herstellung von gegen fsme-virusinfektionen wirksamen vakzinen
DE3650175T3 (de) * 1985-04-29 2007-09-06 Bio-Rad Laboratories, Inc., Hercules Synthetische antigene zum nachweis von aids.
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
WO1988003032A1 (en) * 1986-10-27 1988-05-05 Fournier Maurielle J Diagnosis of and vaccine for japanese encephalitis virus and related viruses
EP0284791B1 (de) * 1987-03-20 1995-05-03 IMMUNO Aktiengesellschaft DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung
JPH084508B2 (ja) * 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
GB8821077D0 (en) * 1988-09-08 1988-10-05 Wellcome Found Peptides

Also Published As

Publication number Publication date
SE9002671D0 (sv) 1990-08-16
WO1992003475A1 (en) 1992-03-05
EP0546031A1 (en) 1993-06-16
AU649473B2 (en) 1994-05-26
AU8400291A (en) 1992-03-17
SE470074B (sv) 1993-11-01

Similar Documents

Publication Publication Date Title
DK0610250T3 (da) Vaccine med porcint reproduktivt respiratorisk syndrom og diagnose heraf
NO893894D0 (no) Non-a, nok-b hepatittvirus antigen-peptid.
Halstead Dengue and hemorrhagic fevers of Southeast Asia.
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
ATE109795T1 (de) Htlv-iii umhüllende peptiden.
ES2170152T3 (es) Virus de la hepatitis g y clon molecular del mismo.
Sylvan et al. Prevalence of antibodies to hepatitis E virus among hemodialysis patients in Sweden
Parker et al. Efficacy of a recombinant Norwalk virus protein enzyme immunoassay for the diagnosis of infections with Norwalk virus and other human “candidate” caliciviruses
SE9002671D0 (sv) Nya peptider, diagnostiska antigener, anvaendning daerav och vacciner
Hayashi et al. Glomerulonephritis associated with feline infectious peritonitis
NO950977L (no) Nye forgrenede hydrid- og klasepeptider som er effektive ved diagnostisering og påvisning av ikke-A, ikke-B hepatit
Goh et al. Acute haemorrhagic conjunctivitis: seroepidemiology of coxsackievirus A24 variant and enterovirus 70 in Singapore
Nigro et al. Parvovirus infection in children with AIDS: high prevalence of B19-specific immunoglobulin M and G antibodies
KR970706300A (ko) E형 간염 파키스탄형 균주의 재조합 단백질 및 이를 이용한 진단방법과 백신(recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines)
DK0491713T3 (da) Rubella El-peptider og C-peptider
DE68928933D1 (de) Faser-hemagglutinin von b. pertussis
SE9101863D0 (sv) Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
Nakajima et al. Demonstration of antigenic identity between purified equine infectious anemia virus and an antigen extracted from infected horse spleen
Stanley et al. Studies on Australian Strains of Coxsackie Virus (Groups A and B).
Brown et al. Fluorescent antibody responses of cases and contacts of hand, foot, and mouth disease
EP0250128A3 (en) Novel virus isolated from patients with aids
ATE540052T1 (de) Neue peptide, die epitope des humanen herpesvirus 8 darstellen
SU1105188A1 (ru) Способ диагностики острой стадии вирусного гепатита В.
Mangiafico et al. Isolation and identification of Venezuelan equine encephalitis virus from a human in Panama.
RU93026692A (ru) Набор для дифференциальной диагностики омской геморрагической лихорадки и клещевого энцефалита

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 9002671-7

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 9002671-7

Format of ref document f/p: F